HCM
ALGS icon

Heights Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Heights Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-241,500
Closed -$1.99M – 164
2025
Q1 		$1.99M Buy
+241,500
New +$5.29M 0.94% 24

Other funds holding ALGS

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Heights Capital Management's ALGS Position: Q2 2025 in Review

Heights Capital Management sold out of Aligos Therapeutics (ALGS) in Q2 2025, closing a stake of 241,500 shares — an estimated $1.99M sold.

Heights Capital Management first reported a position in ALGS in Q1 2025 and held it in 1 quarter. The position peaked at $1.99M in Q1 2025. 37 funds tracked by Wall St. Rank hold ALGS as of Q2 2025.

  • Heights Capital Management reported no remaining Aligos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Heights Capital Management sold 241,500 Aligos Therapeutics shares in Q2 2025, an estimated $1.99M.
  • Heights Capital Management first reported a position in Aligos Therapeutics in Q1 2025 and held it in 1 quarter.
  • Heights Capital Management's Aligos Therapeutics position peaked at $1.99M in Q1 2025.
  • 37 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2025.

Based on Heights Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.